



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

U.S. APPLICATION NO.		FIRST NAMED APPLICANT	ATTY, DOCKET NO.	
09/856050		UEMURA	H UEMURA 8	
			INTERNATIONAL APPLICATION NO.	
BROWDY AND NEIM 624 NINTH STREET			PCT/JP99/06474	
WASHINGTON, DC 20001			I.A. FILING DATE PRIORITY DATE	
			19 NOV 99 20 NOV 98	
			DATE MAILED: 20 JUN 2001	
NOTIFICATION	OF MISSING R	EQUIREMENTS UNDE NATED/ELECTED OFF	R 35 U.S.C. 371 IN THE UNITED	
1. The following items to Office as a D a D S as a C A C C A C A C A C A C A C A C A C A	nave been submitted by esignated Office (37 C	y the applicant or the IB to the UEFR 1.494) an Elected Offi Indication of Small E on. Translation of the interpretation	United States Patent and Trademark ce (37 CFR 1.495):	
Priority Doc	ument. onal Preliminary Exar	' nination Report in English and i		
∐ Translation o	of Annexes to the Inter	national Preliminary Examination	on Report into English.	
2. Applicant has reque the indicated items in para prior to 20 or 30 months i U.S. Basic N	ngraph 3 below. The liftom the priority date	Basic National Fee and the copy	not filed the following indicated items and/or of the international application must be filed onal application.	
3. The following items Macceptance under 35 U.S.	fUST be furnished wit C. 371:	thin the period set forth below in	order to complete the requirements for	
later tha The cur Transla b. Processing appropr c. Oath or de the appl	an the appropriate 20 c rent translation is defe- tion. If ee for providing the iate 20 or 30 months f claration of the invent- ication (preferably by	translation of the application and from the priority date (37 CFR 1 ors, in compliance with 37 CFR the International application num	ate. In the attached Notice of Defective d/or the Annexes later than the .492(f)). 1.497(a) and (b), properly identifying mber and international filing date). A	
date. The curl indicated	rent oath or declaration d on the attached PCT	n does not comply with 37 CFR	1.497(a) and (b) for the reasons	
			propriate 20 or 30 months from the	
 Additional claim fees of 	applicant must submit	large entity small entity the additional claim fees or cano	, including any required multiple dependent sel the additional claims for which fees are	
5. Applicant has not su PCT/DO/EO/920.	abmitted the required s	sequence listing pursuant to 37 C	CFR 1.821-1.825. See attached	
MONTHS FROM THE I	DATE OF THIS NOT FOR THE APPLICA	TICE OR BY 22 OR 32 MONT ATION, WHICHEVER IS LAT	BE SUBMITTED WITHIN TWO (2) IHS (where 37 CFR 1.495 applies) FROM IER. FAILURE TO PROPERLY	
The time period set above 1.136(a).	may be extended by fi	iling a petition and fee for extens	sion of time under the provisions of 37 CFR	
annexes will be cancelled.	A processing fee will adments are cancelled	ll be required if submitted later t since a translation was not provi	no later than the time period set above or the han 20 or 30 months from the priority date. ided by the appropriate 20 (37 CFR 1.494(d))	
		the United States Patent and Trans. application no. shown above.	rademark Office must be mailed to the	
A c Enclosed: PCT/DO/Ed PTO-875	0/917 🔠	ce MUST be returned we Notice of Defective Translation PCT/DO/EO/920	•	
7,10-9,2	(<u>x</u>)	Vo	nda M. Wallace	
ORM PCT/DO/EO/905 (March 2001)		703-305-3736	



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

J.S. APPLICATION NO.	FIRST NAMED APPLICANT	FIRST NAMED APPLICANT		
09/856050	UEMURA	н	UEMURA 8	
		INTERNATIONAL APPLICATION NO.		
ROWDY AND NEIMARK 24 NINTH STREET N W SUITE 300		PCT/JP9	PCT/JP99/06474	
VASHINGTON, DC 20001		I.A. FILING DATE	PRIORITY DATE	
		19 NOV 99	20 NOV 98	

PATENT ADDITIONS

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as a amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:
(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.
i

Telephone: 703-305-3736

FORM PCT/DO/EO/920 (March 2001)